As previously reported in this blog, the U.S. Food and Drug Administration (FDA) announced in January, 2014, that it was launching an investigation into whether FDA-approved testosterone products are causing strokes, heart attacks and even death. Several studies have shown that use of testosterone replacement therapies, such as AndroGel and Axiron, for the dubious medical condition “Low T” actually increases the risk of heart attacks and strokes in men using the product.
Although in its beginning stages, several lawsuits have been filed in the Federal District Court in Chicago, Ill., the district where Abbvie, the maker of AndroGel, is headquartered. The U.S. Judicial Panel on Multidistrict Litigation has now ruled that these cases, and cases that will follow, will be consolidated into a MDL, much as transvaginal mesh and Stryker hip cases were. The new MDL will be styled ‘In re: Testosterone Replacement Therapy Products Liability Litigation’ and will include not just cases brought against Abbvie, but those brought against several other manufacturers. We will continue to monitor these developments and will investigate claims involving these testosterone therapies and “Low T”.
SUGARMAN is investigating claims where patients have suffered heart attacks, strokes or embolic events such as deep vein thrombosis or pulmonary emboli as a result of testosterone replacement therapies such as AndroGel, Axiron and Androderm. If you or a loved one has suffered a significant cardiovascular event while taking or soon after discontinuing testosterone replacement therapy, please fill out a Contact Form, call us at 617-542-1000 or firstname.lastname@example.org.